| Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
| Company Introduction | 美迪西是一家专业的生物医药临床前综合研发服务CRO，为全球的医药企业和科研机构提供全方位的符合国内及国际申报标准的一站式新药研发服务。公司服务涵盖医药临床前新药研究的全过程，主要包括药物发现、药学研究及临床前研究。药物发现研发服务项目包括蛋白靶标验证、结构生物学、化学合成、化合物活性筛选及优化；药学研究包括原料药与制剂工艺研究、质量标准和稳定性研究；临床前研究包括药效学、药代动力学、毒理学安全性评价研究等。 我们关注全球医药行业创新发展的需求，立足于创新药物研发的关键环节，凭借服务国内外生物医药行业所积累的经验，构建涵盖药物发现、药学研究以及临床前研究关键技术的综合性技术平台，为全球生物医药行业提供全方位新药临床前研发服务。 | ||||||||||||||||||||||||
| Main Business | 通过研发技术平台向药企及科研单位提供药物发现与药学研究、临床前研究的医药研发服务 | ||||||||||||||||||||||||
| Legal Representative | 陈金章 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 薛超 | ||||||||||||||||||||||||
| Solicitors | 北京金诚同达律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-58591500 | ||||||||||||||||||||||||
| Fax No | 021-58596369 | ||||||||||||||||||||||||
| Website | www.medicilon.com.cn | ||||||||||||||||||||||||
| IR@medicilon.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 05/11/2019 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.260 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 18.644 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.794B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |